![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5F1E |
Gene summary for ATP5F1E |
![]() |
Gene information | Species | Human | Gene symbol | ATP5F1E | Gene ID | 514 |
Gene name | ATP synthase F1 subunit epsilon | |
Gene Alias | ATP5E | |
Cytomap | 20q13.32 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P56381 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
514 | ATP5F1E | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 8.88e-14 | -1.33e+00 | 0.1622 |
514 | ATP5F1E | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.70e-57 | -1.33e+00 | 0.1575 |
514 | ATP5F1E | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 2.07e-62 | -1.33e+00 | 0.1545 |
514 | ATP5F1E | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 8.46e-50 | -1.33e+00 | 0.1569 |
514 | ATP5F1E | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 4.87e-07 | -1.33e+00 | 0.1532 |
514 | ATP5F1E | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 4.90e-11 | -1.33e+00 | 0.1541 |
514 | ATP5F1E | P1_S1_AK | Human | Skin | AK | 3.82e-38 | 6.59e-01 | -0.3399 |
514 | ATP5F1E | P2_S3_AK | Human | Skin | AK | 4.57e-35 | 6.59e-01 | -0.3287 |
514 | ATP5F1E | P2_S4_SCCIS | Human | Skin | SCCIS | 2.20e-32 | 7.02e-01 | -0.3043 |
514 | ATP5F1E | P3_S6_AK | Human | Skin | AK | 6.09e-24 | 6.22e-01 | -0.3256 |
514 | ATP5F1E | P4_S8_cSCC | Human | Skin | cSCC | 1.38e-40 | 7.32e-01 | -0.3095 |
514 | ATP5F1E | P5_S10_cSCC | Human | Skin | cSCC | 2.99e-82 | 9.89e-01 | -0.299 |
514 | ATP5F1E | P1_cSCC | Human | Skin | cSCC | 7.24e-12 | -5.57e-01 | 0.0292 |
514 | ATP5F1E | P2_cSCC | Human | Skin | cSCC | 1.20e-21 | -5.57e-01 | -0.024 |
514 | ATP5F1E | P4_cSCC | Human | Skin | cSCC | 4.19e-18 | -5.57e-01 | -0.00290000000000005 |
514 | ATP5F1E | P10_cSCC | Human | Skin | cSCC | 9.06e-18 | -5.57e-01 | 0.1017 |
514 | ATP5F1E | cSCC_p1 | Human | Skin | cSCC | 4.98e-17 | -5.57e-01 | -0.1916 |
514 | ATP5F1E | cSCC_p10 | Human | Skin | cSCC | 2.19e-17 | -5.57e-01 | -0.2095 |
514 | ATP5F1E | cSCC_p11 | Human | Skin | cSCC | 1.13e-16 | -5.57e-01 | -0.2102 |
514 | ATP5F1E | cSCC_p3 | Human | Skin | cSCC | 9.58e-18 | -5.57e-01 | -0.2085 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:00159857 | Breast | Precancer | energy coupled proton transport, down electrochemical gradient | 16/1080 | 26/18723 | 4.15e-14 | 9.65e-12 | 16 |
GO:00159867 | Breast | Precancer | ATP synthesis coupled proton transport | 16/1080 | 26/18723 | 4.15e-14 | 9.65e-12 | 16 |
GO:00427766 | Breast | Precancer | mitochondrial ATP synthesis coupled proton transport | 13/1080 | 19/18723 | 1.43e-12 | 2.74e-10 | 13 |
GO:00067547 | Breast | Precancer | ATP biosynthetic process | 21/1080 | 57/18723 | 2.31e-12 | 4.26e-10 | 21 |
GO:00068398 | Breast | Precancer | mitochondrial transport | 45/1080 | 254/18723 | 1.37e-11 | 1.88e-09 | 45 |
GO:00092067 | Breast | Precancer | purine ribonucleoside triphosphate biosynthetic process | 22/1080 | 68/18723 | 1.41e-11 | 1.88e-09 | 22 |
GO:00091457 | Breast | Precancer | purine nucleoside triphosphate biosynthetic process | 22/1080 | 69/18723 | 1.95e-11 | 2.43e-09 | 22 |
GO:00092017 | Breast | Precancer | ribonucleoside triphosphate biosynthetic process | 22/1080 | 74/18723 | 9.18e-11 | 1.00e-08 | 22 |
GO:00091448 | Breast | Precancer | purine nucleoside triphosphate metabolic process | 24/1080 | 88/18723 | 9.66e-11 | 1.03e-08 | 24 |
GO:00092057 | Breast | Precancer | purine ribonucleoside triphosphate metabolic process | 23/1080 | 82/18723 | 1.27e-10 | 1.34e-08 | 23 |
GO:00091427 | Breast | Precancer | nucleoside triphosphate biosynthetic process | 23/1080 | 85/18723 | 2.82e-10 | 2.69e-08 | 23 |
GO:00091997 | Breast | Precancer | ribonucleoside triphosphate metabolic process | 23/1080 | 89/18723 | 7.65e-10 | 6.66e-08 | 23 |
GO:00091418 | Breast | Precancer | nucleoside triphosphate metabolic process | 26/1080 | 112/18723 | 7.72e-10 | 6.66e-08 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
514 | ATP5F1E | TRANSPORTER | glucocorticoids | 26307125 | ||
514 | ATP5F1E | TRANSPORTER | etanercept | ETANERCEPT | 26307125 | |
514 | ATP5F1E | TRANSPORTER | adalimumab | ADALIMUMAB | 26307125 | |
514 | ATP5F1E | TRANSPORTER | certolizumab pegol | 26307125 | ||
514 | ATP5F1E | TRANSPORTER | methotrexate | METHOTREXATE | 26307125 | |
514 | ATP5F1E | TRANSPORTER | infliximab | INFLIXIMAB | 26307125 |
Page: 1 |